Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | PRTN3 | P24158 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10483720 | 0.86 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL22369614 | 0.85 | ELANE (0.86) | ELANEPRTN3 | |
| SCHEMBL4888012 | 0.85 | ELANE (0.71) | ELANEPPARA | |
| SCHEMBL16189796 | 0.85 | ELANE (0.76) | ELANEPRTN3 | |
| SCHEMBL3657615 | 0.85 | ELANE (0.76) | ELANEPRTN3 | |
| SCHEMBL10159814 | 0.84 | ELANE (0.54) | ELANEPPARGPPARALTA4HTHRB | |
| SCHEMBL14870980 | 0.83 | ELANE (0.73) | ELANEPRTN3 | |
| SCHEMBL10973406 | 0.83 | ELANE (0.73) | ELANEPRTN3 | |
| SCHEMBL7276499 | 0.83 | ELANE (0.73) | ELANEPRTN3 | |
| SCHEMBL9299504 | 0.83 | ELANE (0.73) | ELANEPRTN3THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163095-A1 | BIS-PROTECTED, ACTIVATED GUANINE MONOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-22 | — | — | US | claimed |
| CN-113631564-B | Method for producing oligonucleotide having phosphorothioate site | 味之素株式会社 | 2025-02-25 | — | — | CN | claimed |
| EP-4486752-A1 | BIS-PROTECTED, ACTIVATED GUANINE MONOMERS | Eisai R&D Management Co., Ltd. (JP) | 2025-01-08 | — | — | EP | claimed |
| EP-3015467-B1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO KK (JP) | 2024-12-04 | — | — | EP | claimed |
| CN-117586307-B | PMO guanosine monomer synthesis method | 凯莱英生命科学技术(天津)有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117586307-A | PMO guanosine monomer synthesis method | 凯莱英生命科学技术(天津)有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2023167908-A1 | BIS-PROTECTED, ACTIVATED GUANINE MONOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-07 | — | — | WO | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-4695265-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4678626-A1 | LONG-CHAIN ALKENYLOXY-SUBSTITUTED BENZOYL DERIVATIVE AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME | Spera Pharma, Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001902-A1 | IMPROVED OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-12509484-B2 | Method of producing nucleic acid compound, and nucleic acid compound | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-4093802-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | disclosed |
| US-4093804-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | disclosed |
| US-4045438-A | Cephalosporin antibiotics | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1977-08-30 | — | — | US | disclosed |
| US-4031083-A | Cephalosporin antibiotics | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1977-06-21 | — | — | US | disclosed |
| US-4026887-A | Cephalosporin antibiotics | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1977-05-31 | — | — | US | disclosed |
| US-3994875-A | CEPHALOSPORINS, PENICILLINS | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-11-30 | — | — | US | disclosed |
| US-3948904-A | ANTIBIOTICS | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | ELANE 3523/4885PPARG 3838/4885PPARA 2664/4885 |
| US-12509484-B2 | Method of producing nucleic acid compound, and nucleic acid compound | NSUN2, RNASEH1, XRN2 | ELANE 3664/4885PPARG 2291/4885PPARA 1530/4885 |
| US-20260001902-A1 | IMPROVED OLIGONUCLEOTIDE SYNTHESIS | MED1, POLRMT, CPSF6 | ELANE 4305/4885PPARG 1458/4885PPARA 1814/4885 |
| US-20250163095-A1 | BIS-PROTECTED, ACTIVATED GUANINE MONOMERS | GDA, REV1, UNG | ELANE 2418/4885PPARG 657/4885PPARA 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.